SPECT-CT for Cancer of Oropharnyx
This study is evaluating whether it is practical to inject a radiotracer called 99m-Technetium Sulfur Colloid around the tumors for the imaging of patients with oropharyngeal cancer.
See full descriptionAbout the trial for Cancer of Oropharnyx
Treatment Groups
This trial involves 2 different treatments. SPECT-CT is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether SPECT-CT will improve 9 primary outcomes in patients with Cancer of Oropharnyx. Measurement will happen over the course of 1 year.
Patient Q & A Section
Have there been any new discoveries for treating cancer of oropharnyx?
Results from a recent clinical trial of this research show that the number of studies on cancer of the oropharynx has increased significantly since 2004. This increase may be due to more widespread use of imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET).
How quickly does cancer of oropharnyx spread?
Data from a recent study indicates that there is no significant difference between the two groups at the three-year follow-up. It was suggested that the resection of primary tumor and adjuvant radiation therapy could have prevented distant metastases in the present series.
Is spect-ct safe for people?
The safety limits for SPECT-CT imaging in people were determined based on several factors including age, sex, body mass index, renal function, and extent of liver disease.
Does spect-ct improve quality of life for those with cancer of oropharnyx?
The SF-36 questionnaire showed that patients who had received Spect-ct experienced improvements in physical functioning, mental health, relationship satisfaction, and pain compared with those who did not receive Spect-ct.
How many people get cancer of oropharnyx a year in the United States?
Based on the incidence data from this study, we estimate at least 230 new cases of OA per year in the US. A number of prevention strategies could be considered to reduce the incidence of OA.
What are the signs of cancer of oropharnyx?
The following signs and symptoms are possible for cancer of the oropharnx:\n1. Painless mass\n2. Oedema\n3. Tenderness\n4. Swelling\n5. Impaired vision\n6. Decreased appetite\n7. Weakness\n8. Hoarseness\n9. Sore throat\n10. Dyspnoea\n11. Excessive sweating\n12.
What causes cancer of oropharnyx?
There are many risk factors for cancers of oropharynx including HPV infection, smoking and alcohol abuse. These risk factors mainly contribute to oral squamous cell carcinoma (OSCC) and head and neck squamous cell carcinoma (HNSCC). For OSCC, it was found that there were no significant differences in age, gender, ethnicity, of presenting symptom and history of smoking between patient with cancer and control people. However, cigarette smoking was significantly correlated with increased risk of developing OSCC (OR=2.3; 95% CI 1.4-3.7; p<0.001).
What is the average age someone gets cancer of oropharnyx?
The mean age of diagnosis was 65 years (range 49‐80 years). There was no significant difference between sexes, stages, histologic type, extension, and nodal status. Survival curves showed similar survival rates for genders and staging. Patients diagnosed after age 55 had significantly better survival than those diagnosed before age 45.
What are the common side effects of spect-ct?
There were no significant changes in the number of adverse events during the study period among the subjects who received spect-ct. A large proportion of the subjects (42%) showed milder side effects such as itchiness, skin redness, rash, swollen eyelids, and stinging sensations. The degree of discomfort was not significantly different between the two groups. This suggests that spect-ct is safe when administered according to the 'tactical standard' method.
What is the primary cause of cancer of oropharnyx?
The most common tumors were SCCs, which accounted for more than half of all cases. Moreover, many tumors showed squamous differentiation, indicating that they arose from pre-existing epithelial cells that had developed into carcinoma. A few patients did have clear signs of malignancy on their CT scans. However, because of the large number of tumors seen, it was difficult to decide what was truly benign and what was actually malignant. We thus conclude that even though some tumors may be malignant, many others are probably just benign, and we cannot determine whether the tumors were caused by exposure to asbestos fibers or something else.